Showing 1 - 20 results of 4,303 for search '"Journal for ImmunoTherapy of Cancer"', query time: 0.32s Refine Results
  1. 1
    528 Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b

    528 Sexual dimorphism in myeloid-derived suppressor cells promote GBM progression in females via IL-1b by Alice Lo, Peter Sims, Defne Bayik, Yadi Zhou, Chihyun Park, Chngjin Hong, Danielle Silver, Dionysios Watson, Tae Hyun Hwang, Feixiong Cheng, Antonio Iavarone, Justin Lathia

    Published 2020-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  2. 2
    Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy

    Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy by Chun-Yu Chen, Mohammed G Ghonime, Uksha Saini, Michael C Kelly, Justin C Roth, Pin-Yi Wang, Katherine Miller, Ilse Hernandez-Aguirre, Yeaseul Kim, Xiaokui Mo, Joseph R Stanek, Tim Cripe, Elaine Mardis, Kevin A Cassady

    Published 2021-10-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  3. 3
    Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

    Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy by Wei Liu, Yan Xu, Yi Wang, Lugui Qiu, Ting Xie, Xiaojuan Wang, Huimin Liu, Tonghui Ma, Jianxiang Wang, Gang An, Weiwei Sui, Hesong Zou, Chunyang Wang, Chen Qiu, Dandan Shan, Wenyang Huang, Shuhua Yi, Dehui Zou

    Published 2024-03-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  4. 4
    826 Differential effect of NKG2A blockade on peripheral and intra-tumoral CD8 T cell response induced by KISIMA – VSV-GP-TAg heterologous prime-boost vaccination

    826 Differential effect of NKG2A blockade on peripheral and intra-tumoral CD8 T cell response induced by KISIMA – VSV-GP-TAg heterologous prime-boost vaccination by Matteo Rossi, Elodie Belnoue, Susanna Carboni, Wilma Besson-Di Berardino, Erika Riva, Mati Moyat, Laetitia Devy-Dimanche

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  5. 5
    TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells

    TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells by Zhigang Tian, Xiaohu Zheng, Yingying Huang, Jiacheng Bi, Xiaomeng Jin, Chaoyue Zheng, Haoyu Sun

    Published 2023-02-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  6. 6
    1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors

    1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with adva... by Yang Xu, Alexander Starodub, Cesar Perez, Yuping Li, Andrae Vandross, Jason Henry, Alexander I Spira, Xuebin Liao

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  7. 7
    908 Humanized model for assessment of therapies targeting either lymphoid or myeloid compartment: enhanced evaluation of clinical relevancy & translatability

    908 Humanized model for assessment of therapies targeting either lymphoid or myeloid compartment: enhanced evaluation of clinical relevancy & translatability by Charles Dumontet, Gaëlle Martin, Chloé Beuraud, Yacine Cherifi, Alexandre Fraichard, Patricia Isnard-Petit, Kader Thiam, Angus Sinclair, Poonam Yakkundi, Florence Renart-Depontieu, Morgane Denis, Léa Magadoux, Elsa Kress, Ludovic Bourre, Dean Campbell, Astrid Doerner

    Published 2021-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  8. 8
    900 Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner

    900 Depleting non-canonical, cell-intrinsic PD-L1 signals induces synthetic lethality to small molecule DNA damage response inhibitors in an immune independent and dependent manner... by Tyler Curiel, Lauren Byers, Yilun Deng, Alvaro Padron, Harshita Gupta, Anand Kornepati, Clare Murray, Ratna Vadlamudi, Barbara Avalos, Cody Rogers, Kavya Ramkumar, Zexuan Liu, Eloise Dray, Weixing Zhao, Patrick Sung

    Published 2021-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  9. 9
    Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity

    Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity by Yu Xia, Baiyong Li, Zhongmin Maxwell Wang, Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Tailong Qu, Chunshan Jin

    Published 2022-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  10. 10
    810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors

    810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors by Dan Liu, Jing Yang, Lin Shen, Yue Yang, Ting Xu, Jifang Gong, Zhi Dong, June Xu, Yakun Qi, Jie Men, Paul Kong

    Published 2020-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  11. 11
    CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value

    CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value by Yan Yang, Fang-Shu Ou, Emil Lou, Joanne Xiu, Hiroyuki Arai, Francesca Battaglin, Heinz-Josef Lenz, Richard M Goldberg, Anthony F Shields, Yasmine Baca, Philip A Philip, John L Marshall, W Michael Korn, Andreas Seeber, Natsuko Kawanishi, Jingyuan Wang, Shivani Soni, Wu Zhang, Shannon M Mumenthaler, Joshua Millstein, Priya Jayachandran, Federico Innocenti, Annika Lenz, Sandra Algaze, Taline Khoukaz, Evanthia Roussos Torres, Jim P Abraham, Benjamin A Weinberg, Alan P Venook

    Published 2024-01-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  12. 12
    484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

    484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors by Stephane Champiat, Aurélien Marabelle, Aung Naing, Filip Janku, Patricia LoRusso, David Béchard, Elena Garralda, Vladimir Galvao, Peter Grell, Richard Sachse, Joachim Kiemle-Kallee

    Published 2021-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  13. 13
    Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer

    Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer by Heng Zhang, Chao Lin, Hongyong He, Hao Liu, Ruochen Li, He Li, Jiejie Xu, Fei Shao, Yun Gu, Hanji Fang, Jieti Wang, Kunpeng Lv, Mengyao Sun

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  14. 14
    627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer

    627 The DLL3-targeted half-life extended bispecific T cell engager (HLE BiTE®) immune-oncology therapy AMG 757 has potent antitumor activity in neuroendocrine cancer by Keegan Cooke, Jinghui Zhan, Juan Estrada, Marie-Anne Damiette Smit, Aditya Shetty, Jonathan Werner, Fei Lee

    Published 2020-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  15. 15
    Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells

    Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells by Christine Brown, Wen-Chung Chang, Renate Starr, Brenda Aguilar, Kurt Jenkins, Miso Park, Cheng-Fu Kuo, Yi-Chiu Kuo, Alfur Fu-Hsin Hung, Jonathan Hibbard, John C Williams

    Published 2022-06-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  16. 16
    357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma

    357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refra... by Cheryl Li, Lei Shen, Sabrina Collins, Adarsh Joshi, Subhasree Das, Kaveri Suryanarayan, Dean Bottino, Michael Curley, Dannie Wang, Michael Abadier, Ryan Larson, Xavier Parot

    Published 2020-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  17. 17
    1032 Early remodelling of CD4 T cell differentiation in lung squamous carcinogenesis

    1032 Early remodelling of CD4 T cell differentiation in lung squamous carcinogenesis by Vítor Teixeira, Kate Davies, Peter Campbell, Bart Vanhaesebroeck, Sam Janes, Kate Gowers, Amalie Kai Bentzen, Teerapon Sahwangarrom, Claudia Peinador Marin, Sam Gamble, Zoe Whiteman, Seng Ung, Lukas Kalinke, Ahmed Alhendi, Adam Pennycuick, Sandra Gomez Lopez, Andrei Enica, Amber Rogers, Kane Foster, Moritz Przybilla, James L Reading

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  18. 18
    Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer

    Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer by Guoliang Wang, Feng Li, Gaopeng Li, Ting Liu, Fenqing Chi, Yuqi Jia, Quankai Mu, Keru Qin, Xiaoxia Zhu, Baixue Xu, Guangen Feng, Yuhu Niu, Tao Gong, Hongwei Zhang, Xiushan Dong, Jinfeng Ma, Zefeng Gao, Kai Tao, Baofeng Yu

    Published 2021-03-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article
  19. 19
    222-K Integrated immunoprofiling and RNA sequencing (RNA-seq) for anti-PD-1 response prediction in head and neck squamous cell carcinomas (HNSCC)

    222-K Integrated immunoprofiling and RNA sequencing (RNA-seq) for anti-PD-1 response prediction in head and neck squamous cell carcinomas (HNSCC) by Madalina Tuluc, Jennifer Johnson, Adam J Luginbuhl, Vladimir Kushnarev, Alexander Bagaev, Anastasia Nikitina, Alexander Zaytcev, Eric Mastrolonardo, Alban J Linnenbach, Anastasia Sobol, Tatiana Vasileva, Arseniy Sokolov, Daniiar Dyikanov, Evgeniia Alekseeva, Andrey Tyshevich, Christopher JH Davitt, Michael F Goldberg, Cagdas Tazearslan

    Published 2023-11-01
    “…Journal for ImmunoTherapy of Cancer…”
    Article
  20. 20
    Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

    Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy by Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang, Hang-Ping Yao

    Published 2019-09-01
    “…Journal for ImmunoTherapy of Cancer…”
    Get full text
    Article

Search Tools: